{"disease":{"id":"head-and-neck-cancer","name":"Head And Neck Cancer","therapeutic_area":"Oncology","data":{"aiSummary":"The treatment landscape for head and neck cancer is evolving, with a shift towards personalized approaches. Immunotherapy, particularly with pembrolizumab, has shown significant benefit in recurrent/metastatic disease, and is now being explored in earlier settings. Research continues to focus on refining the use of targeted therapies and optimizing combinations of chemotherapy, radiation, and immunotherapy. The pipeline includes novel agents and combinations aimed at improving outcomes and reducing treatment-related toxicities.","drug_count":5,"description":"Head and neck cancer encompasses a group of cancers that develop in the head and neck region, including the oral cavity, pharynx, larynx, and nasal cavity. The majority of head and neck cancers are squamous cell carcinomas, often linked to tobacco and alcohol use, as well as human papillomavirus (HPV) infection. Treatment typically involves a combination of surgery, radiation therapy, chemotherapy, and targeted therapies.","subtype_count":9},"enrichment_level":2,"last_enriched_at":null,"visit_count":0,"created_at":"2026-03-25T12:16:34.930Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":3,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"nivolumab","indication_name":"Head and neck cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Opdivo","generic_name":"nivolumab","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Programmed cell death protein 1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":79,"revenue":"9200","mechanism":"Opdivo works by blocking the PD-1 receptor on immune cells, allowing them to attack cancer cells."},{"drug_id":"cetuximab","indication_name":"Head and neck cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Erbitux","generic_name":"cetuximab","company_name":"Imclone","drug_phase":"marketed","molecular_target":"Epidermal growth factor receptor","drug_class":"Epidermal Growth Factor Receptor Antagonist [EPC]","quality_score":62,"revenue":null,"mechanism":"Erbitux works by binding to the Epidermal Growth Factor Receptor (EGFR) on cancer cells, blocking the receptor's ability to stimulate cell growth and division."},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of head and neck cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"erbitux","indication_name":"Head and neck cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Erbitux","company_name":"Hellenic Oncology Research Group","drug_phase":"marketed","molecular_target":"Epidermal growth factor receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05483374","title":"The Head and Neck Registry of the European Reference Network on Rare Adult Solid Cancers","phase":"","overall_status":"RECRUITING","enrollment_count":13600,"lead_sponsor_name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","has_results":false},{"nct_id":"NCT05117775","title":"Towards A Better Paradigm for Head and Neck Cancer Treatment Applying Artificial Intelligence. HNC-TACTIC.","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Savana Research","has_results":false},{"nct_id":"NCT04075305","title":"The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study","phase":"","overall_status":"RECRUITING","enrollment_count":8000,"lead_sponsor_name":"UMC Utrecht","has_results":false},{"nct_id":"NCT07524114","title":"Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK)","phase":"","overall_status":"RECRUITING","enrollment_count":7000,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT07532538","title":"A Machine Learning-Based Risk Prediction Model for Head and Neck Cancerous Lesions","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":3000,"lead_sponsor_name":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","has_results":false},{"nct_id":"NCT06773039","title":"Assessment of Different Therapeutic Strategies in Patients With Head and Neck Neoplasms Treated With Radiotherapy","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT04825834","title":"DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)","phase":"","overall_status":"COMPLETED","enrollment_count":2992,"lead_sponsor_name":"Delfi Diagnostics Inc.","has_results":false},{"nct_id":"NCT03702309","title":"Liquid Biopsy Evaluation and Repository Development at Princess Margaret","phase":"","overall_status":"RECRUITING","enrollment_count":2500,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT04326088","title":"Postoperative Complication After Free Flap Reconstruction for Head and Neck Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":2004,"lead_sponsor_name":"Chang Gung Memorial Hospital","has_results":false},{"nct_id":"NCT00530049","title":"Measuring Patient Satisfaction With Facial Appearance: Development and Validation of a New Patient-Reported Outcome Measure","phase":"","overall_status":"COMPLETED","enrollment_count":1745,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT00963911","title":"Validation of a Screening Tool in Geriatric Oncology","phase":"NA","overall_status":"COMPLETED","enrollment_count":1674,"lead_sponsor_name":"Institut Bergonié","has_results":true},{"nct_id":"NCT04002713","title":"Comparison of Choosing Free ALT or Free PMT for Reconstruction With Head and Neck Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":1590,"lead_sponsor_name":"Chang Gung Memorial Hospital","has_results":false},{"nct_id":"NCT04478851","title":"EXCEL: Exercise for Cancer to Enhance Living Well","phase":"NA","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"University of Calgary","has_results":false},{"nct_id":"NCT05697198","title":"PRospective REgistry of Advanced Stage CancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine","phase":"","overall_status":"COMPLETED","enrollment_count":1429,"lead_sponsor_name":"Labcorp Corporation of America Holdings, Inc","has_results":false},{"nct_id":"NCT03145077","title":"Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Diagnosing Osteoradionecrosis in Patients With Head and Neck Cancer That Is Primary, Has Come Back, or Has Spread to Other Places in the Body","phase":"NA","overall_status":"RECRUITING","enrollment_count":1400,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05995821","title":"Immunobiology Blood and Tissue Collection of Upper Aerodigestive Malignancies","phase":"","overall_status":"RECRUITING","enrollment_count":1250,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","has_results":false},{"nct_id":"NCT05812027","title":"A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1150,"lead_sponsor_name":"TScan Therapeutics, Inc.","has_results":false},{"nct_id":"NCT02292914","title":"Prospective Analysis of Robot-Assisted Surgery","phase":"NA","overall_status":"UNKNOWN","enrollment_count":1120,"lead_sponsor_name":"Instituto do Cancer do Estado de São Paulo","has_results":false},{"nct_id":"NCT05375266","title":"Immune Biomarker Study for Head and Neck Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":1100,"lead_sponsor_name":"University of Erlangen-Nürnberg Medical School","has_results":false},{"nct_id":"NCT03245788","title":"Effectiveness of Lay Navigators in Meeting Cancer Patients' Non-Clinical Needs: A Pilot Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":1053,"lead_sponsor_name":"Stanford University","has_results":false},{"nct_id":"NCT03017573","title":"Prospective Biobanking Study in Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE)","phase":"NA","overall_status":"RECRUITING","enrollment_count":1050,"lead_sponsor_name":"Institut Curie","has_results":false},{"nct_id":"NCT02741570","title":"Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":947,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT03170960","title":"Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":914,"lead_sponsor_name":"Exelixis","has_results":false},{"nct_id":"NCT06556979","title":"Carotid Artery Stenosis and Ischemic Cerebrovascular Events After Radiotherapy in Patients With Head and Neck Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":907,"lead_sponsor_name":"Chulabhorn Royal Academy","has_results":false},{"nct_id":"NCT02358031","title":"A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":882,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT04541381","title":"The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care","phase":"NA","overall_status":"RECRUITING","enrollment_count":860,"lead_sponsor_name":"University of Chicago","has_results":false},{"nct_id":"NCT06970275","title":"To Assess the Correlation of High-resolution Specimen PET-CT Imaging, Using the XEOS AURA 10 PET-CT, With the Histopathology Results and Long-term Outcome of Patients Undergoing Resective Cancer Surgery.","phase":"","overall_status":"RECRUITING","enrollment_count":850,"lead_sponsor_name":"XEOS Medical","has_results":false},{"nct_id":"NCT05973487","title":"A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":840,"lead_sponsor_name":"TScan Therapeutics, Inc.","has_results":false},{"nct_id":"NCT01846286","title":"Neuropathic Pain in Head and Neck Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":838,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06831903","title":"Radiotherapy of Head and Neck Cancer With SIB","phase":"","overall_status":"RECRUITING","enrollment_count":750,"lead_sponsor_name":"Wuerzburg University Hospital","has_results":false},{"nct_id":"NCT04632173","title":"Head and Neck cancERs International cOviD-19 collabOraTion","phase":"","overall_status":"UNKNOWN","enrollment_count":750,"lead_sponsor_name":"Hellenic Cooperative Oncology Group","has_results":false},{"nct_id":"NCT06755567","title":"Application of MRI Radiomics Features in Neoadjuvant Therapy of Head and Neck Squamous Cell Carcinoma","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":750,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT02997553","title":"Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":744,"lead_sponsor_name":"Institut de Cancérologie de Lorraine","has_results":false},{"nct_id":"NCT06172478","title":"A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":740,"lead_sponsor_name":"Daiichi Sankyo","has_results":false},{"nct_id":"NCT00900419","title":"Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers","phase":"","overall_status":"RECRUITING","enrollment_count":700,"lead_sponsor_name":"University of Colorado, Denver","has_results":false},{"nct_id":"NCT06570486","title":"Contrast Between Traditional Regression Model and AI in Predicting Prolonged Stay Stay After Head and Neck Tumors","phase":"","overall_status":"RECRUITING","enrollment_count":700,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT07027280","title":"Noninvasive Intratumor Heterogeneity Evaluation in HNSCC","phase":"","overall_status":"RECRUITING","enrollment_count":700,"lead_sponsor_name":"First Affiliated Hospital of Chongqing Medical University","has_results":false},{"nct_id":"NCT06116019","title":"Online Adaptive Radiotherapy Using a Novel Linear Accelerator (ETHOS)","phase":"","overall_status":"RECRUITING","enrollment_count":649,"lead_sponsor_name":"Charite University, Berlin, Germany","has_results":false},{"nct_id":"NCT05078047","title":"Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":646,"lead_sponsor_name":"UNICANCER","has_results":false},{"nct_id":"NCT04713449","title":"Enhancing Self Care Among Oral Cancer Survivors: The Empowered Survival Trial","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":643,"lead_sponsor_name":"Rutgers, The State University of New Jersey","has_results":false},{"nct_id":"NCT06827639","title":"In-depth Characterization of Circulating and Infiltrating Immune Subsets and Tumor Cells in Cancer Patients","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":640,"lead_sponsor_name":"Assistance Publique Hopitaux De Marseille","has_results":false},{"nct_id":"NCT01880359","title":"AF CRT +/- Nimorazole in HNSCC","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":640,"lead_sponsor_name":"European Organisation for Research and Treatment of Cancer - EORTC","has_results":false},{"nct_id":"NCT06041555","title":"MRI Guided Radiotherapy and Radiobiological Data: the ISRAR Database (Irm Sequences for Radiobiological Adaptative Radiotherapy)","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT06428994","title":"Risk for Subsequent Osteoradionecrosis in A Transferred Fibula Flap in Head and Neck Cancer Patients Undergoing Segmental Mandibulectomy: a Cohort Study","phase":"","overall_status":"COMPLETED","enrollment_count":580,"lead_sponsor_name":"Chang Gung Memorial Hospital","has_results":false},{"nct_id":"NCT05793151","title":"Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant Therapy","phase":"NA","overall_status":"RECRUITING","enrollment_count":532,"lead_sponsor_name":"Medical University of South Carolina","has_results":false},{"nct_id":"NCT00002695","title":"Analysis of Tumor Tissue and Lymph Nodes Surgically Removed From Patients With Cancers of the Head and Neck","phase":"","overall_status":"COMPLETED","enrollment_count":530,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":false},{"nct_id":"NCT01631552","title":"Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":515,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT04050761","title":"A Study of Nivolumab in Patients With Head and Neck Cancer.","phase":"","overall_status":"COMPLETED","enrollment_count":502,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT05969262","title":"A Bidirectional Study in Exploring the Dynamic Changes of Plasma and Urine Metabolites of Head and Neck Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT05937477","title":"Developing Artificial Intelligence-based Algorism to Predict Side Effects and Symptoms From Chemotherapy","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Sehhoon Park","has_results":false}],"total":50},"guidelines":[{"drug_id":"cetuximab","guideline_body":"FDA label","recommendation":"ERBITUX in combination with radiation therapy for the initial treatment of locally or regionally advanced squamous cell carcinoma of the head and neck (SCCHN).","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"cetuximab","guideline_body":"FDA label","recommendation":"ERBITUX in combination with platinum-based therapy with fluorouracil for the first-line treatment of patients with recurrent locoregional disease or metastatic SCCHN.","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"cetuximab","guideline_body":"FDA label","recommendation":"ERBITUX as a single-agent for the treatment of patients with recurrent or metastatic SCCHN for whom prior platinum-based therapy has failed.","line_of_therapy":"2L+","evidence_grade":"not specified","guideline_year":null}],"source":"Drug Landscape verified database"}